Disease-Modifying Potential of BET Inhibitor Pelabresib (CPI-0610) As Demonstrated By Improvements in Bone Marrow Function and Clinical Activity in Patients with Myelofibrosis - Preliminary Data

被引：5

作者：

Verstovsek, Srdan ^{[1
]}

Salama, Mohamed E. ^{[2
]}

Mascarenhas, John ^{[3
]}

Talpaz, Moshe ^{[4
]}

Mesa, Ruben A. ^{[5
]}

Vannucchi, Alessandro ^{[6
]}

Rampal, Raajit ^{[7
]}

Oh, Stephen T. ^{[8
]}

Olteanu, Horatiu ^{[2
]}

Chiu, April ^{[2
]}

Chen, Dong ^{[2
]}

Hanson, Curtis A. ^{[2
]}

Curto-Garcia, Natalia ^{[9
]}

Taverna, Pietro ^{[10
]}

Cui, Jike ^{[10
]}

Zavidij, Oksana ^{[10
]}

Chen, Zehua ^{[10
]}

Colak, Gozde ^{[10
]}

Efuni, Sergey ^{[10
]}

Keller, Patricia J. ^{[10
]}

Trojer, Patrick ^{[10
]}

Harrison, Claire N. ^{[9
]}

机构：

[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[2] Mayo Clin, Rochester, MN USA

[3] Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY 10029 USA

[4] Univ Michigan, Dept Internal Med, Div Hematol Oncol, Ann Arbor, MI 48109 USA

[5] UT Hlth San Antonio Canc Ctr, Mays Canc Ctr, San Antonio, TX USA

[6] Az Osped Univ Careggi, Florence, Italy

[7] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[8] Washington Univ, Sch Med, St Louis, MO USA

[9] Guys & St Thomas NHS Fdn Trust, London, England

[10] Constellat Pharmaceut, Cambridge, MA USA

来源：

BLOOD | 2021年 / 138卷

关键词：

D O I：

10.1182/blood-2021-152267

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2568

引用

页数：7

共 11 条

[1] Disease-modifying potential of pelabresib demonstrated by improvement in bone marrow function and resulting clinical benefit in patients with myelofibrosis
Platzbecker, U.
Vannucchi, A.
Verstovsek, S.
Salama, M. E.
Mascarenhas, J.
Talpaz, M.
Mesa, R. A.
Rampal, R. K.
Oh, S. T.
Olteanu, H.
Chiu, A.
Chen, D.
Hanson, C. A.
Curto-Garcia, N.
Taverna, P.
Cui, J.
Zavidij, O.
Chang, T. -W
Colak, G.
Harrison, C. N.
ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (SUPPL 2) : 274 - 275
[2] Exploratory Analysis: Potential of pelabresib (CPI-0610), a bromodomain and extra-terminal domain inhibitor, as suggested by analysis of improvements in bone marrow histology and function in patients with myelofibrosis-preliminary data
Harrison, Claire
Verstovsek, Srdan
Salama, Mohamed E.
Mascarenhas, John
Talpaz, Moshe
Mesa, Ruben
Vannucchi, Alessandro M.
Rampal, Raajit K.
Oh, Stephen
Olteanu, Horatiu
Chiu, April
Chen, Dong
Hanson, Curtis A.
Curto-Garcia, Natalia
Taverna, Pietro
Cui, Jike
Zavidij, Oksana
Chang, Tzuu-Wang
Colak, Gozde
Efuni, Sergey
Keller, Patricia
Trojer, Patrick
Mead, Adam J.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 27 - 28
[3] BET Inhibitor Pelabresib (CPI-0610) Combined With Ruxolitinib in Patients With Myelofibrosis - JAK Inhibitor-Naive or With Suboptimal Response to Ruxolitinib - Preliminary Data From the MANIFEST Study
Mascarenhas, John
Kremyanskaya, Marina
Patriarca, Andrea
Harrison, Claire
Bose, Prithviraj
Rampal, Raajit K.
Palandri, Francesca
Devos, Timothy
Passamonti, Francesco
Hobbs, Gabriela
Talpaz, Moshe
Vannucchi, Alessandro
Kiladjian, Jean-Jacques
Verstovsek, Srdan
Hoffman, Ron
Salama, Mohamed E.
Chen, Dong
Taverna, Pietro
Chang, Alex
Colak, Gozde
Klein, Sandra
Gupta, Vikas
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S335 - S336
[4] Pelabresib (CPI-0610) Monotherapy in Patients with Myelofibrosis - Update of Clinical and Translational Data from the Ongoing Manifest Trial
Kremyanskaya, Marina
Mascarenhas, John
Palandri, Francesca
Vannucchi, Alessandro
Verstovsek, Srdan
Harrison, Claire N.
Bose, Prithviraj
Schiller, Gary J.
Rampal, Raajit
Drummond, Mark W.
Gupta, Vikas
Patriarca, Andrea
Granacher, Nikki
Scandura, Joseph
Prejzner, Witold
Teichmann, Lino L.
Curto-Garcia, Natalia
Hoffman, Ronald
Colak, Gozde
Ren, Zheng
Bobba, Suresh
Cui, Jike
Efuni, Sergey
Talpaz, Moshe
BLOOD, 2021, 138
[5] Pelabresib (CPI-0610) monotherapy in patients with myelofibrosis-update of clinical and translational data from the ongoing MANIFEST trial
Curto-Garcia, Natalia
Kremyanskaya, Marina
Mascarenhas, John
Palandri, Francesca
Vannucchi, Alessandro M.
Verstovsek, Srdan
Harrison, Claire
Bose, Prithviraj
Schiller, Gary J.
Rampal, Raajit
Drummond, Mark W.
Gupta, Vikas
Patriarca, Andrea
Granacher, Nikki
Scandura, Joseph
Prejzner, Witold
Teichmann, Lino L.
Hoffman, Ronald
Colak, Gozde
Ren, Zheng
Bobba, Suresh
Cui, Jike
Efuni, Sergey
Talpaz, Moshe
Mead, Adam J.
BRITISH JOURNAL OF HAEMATOLOGY, 2022, 197 : 75 - 76
[6] The BET Inhibitor, CPI-0610, Promotes Myeloid Differentiation in Myelofibrosis Patient Bone Marrow and Peripheral CD34+Hematopoietic Stem Cells
Mertz, Jennifer A.
Keller, Patricia J.
Meyer, Rosana D.
Zavidij, Oksana
Cui, Jike
Kiladjian, Jean-Jacques
Verstovsek, Srdan
Gupta, Vikas
Talpaz, Moshe
Harrison, Claire
Mead, Adam J.
Mesa, Ruben
Mascarenhas, John
Senderowicz, Adrian
Colak, Gozde
Shao, James
Luptakova, Katarina
Humphrey, Jeffrey S.
Wang, Jing
Trojer, Patrick
Salama, Mohamed E.
BLOOD, 2020, 136
[7] THE BET INHIBITOR, CPI-0610, PROMOTES MYELOID DIFFERENTIATION IN MYELOFIBROSIS (MF) PATIENT BONE MARROW AND PERIPHERAL CD34+HEMATOPOIETIC STEM CELLS
Vannucchi, A.
Keller, P. J.
Meyer, R. D.
Zavidij, O.
Cui, J.
Verstovsek, S.
Gupta, V.
Talpaz, M.
Harrison, C.
Mead, A. J.
Mesa, R.
Mascarenhas, J.
Colak, G.
Shao, J.
Luptakova, K.
Humphrey, J. S.
Wang, J.
Trojer, P.
Salama, M. E.
HAEMATOLOGICA, 2021, 106 (10) : 51 - 51
[8] Clinical Benefit of Pelabresib (Cpi-0610) in Combination with Ruxolitinib in JAK Inhibitor Treatment-Naive Myelofibrosis Patients: Interim Efficacy Subgroup Analysis from Arm 3 of the MANIFEST Phase 2 Study
Gupta, Vikas
Kremyanskaya, Marina
Mascarenhas, John
Palandri, Francesca
Patriarca, Andrea
Devos, Timothy
Harrison, Claire
Passamonti, Francesco
Rampal, Raajit
Mead, Adam
Scandura, Joseph
Hobbs, Gabriela
Talpaz, Moshe
Granacher, Nikki
Somervaille, Tim
Hoffman, Ronald
Bose, Prithviraj
Colak, Gozde
Shao, James
Cui, Jike
Bobba, Suresh
Luptakova, Katarina
Verstovsek, Srdan
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S362 - S362
[9] The BET Inhibitor Pelabresib Decreases Inflammatory Cytokines, Improves Bone Marrow Fibrosis and Function, and Demonstrates Clinical Response Irrespective of Mutation Status in Myelofibrosis Patients in the Phase 2 MANIFEST Trial
Zavidij, Oksana
Keller, Patricia
Cui, Jike
Mertz, Jennifer
Salama, Mohamed
Olteanu, Horatiu
Chiu, April
Chen, Dong
Hanson, Curtis A.
Chen, Zehua
Verstovsek, Srdan
Harrison, Claire
Mascarenhas, John
Talpaz, Moshe
Mesa, Ruben
Vannucchi, Alessandro
Rampal, Raajit
Oh, Stephen
Colak, Gozde
Luptakova, Katarina
Humphrey, Jeffrey
Wang, Jing
Trojer, Patrick
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S363 - S364
[10] Potential Disease-Modifying Activity of Imetelstat Demonstrated By Reduction in Cytogenetically Abnormal Clones and Mutation Burden Leads to Clinical Benefits in Relapsed/Refractory Myelofibrosis Patients
Mascarenhas, John
Komrokji, Rami S.
Cavo, Michele
Martino, Bruno
Niederwieser, Dietger
Reiter, Andreas
Scott, Bart L.
Baer, Maria R.
Hoffman, Ronald
Odenike, Olatoyosi
Sherman, Laurie
Dougherty, Souria
Feller, Faye
Berry, Tymara
Sun, Libo
Wan, Ying
Rizo, Aleksandra
Huang, Fei
Kiladjian, Jean-Jacques
BLOOD, 2020, 136

← 1 2 →